These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36790010)

  • 21. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
    Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
    Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
    Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
    AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-based study of pseudoprogression after chemoradiotherapy in GBM.
    Roldán GB; Scott JN; McIntyre JB; Dharmawardene M; de Robles PA; Magliocco AM; Yan ES; Parney IF; Forsyth PA; Cairncross JG; Hamilton MG; Easaw JC
    Can J Neurol Sci; 2009 Sep; 36(5):617-22. PubMed ID: 19831132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1 - Molecular, morphological and clinical features.
    Le Fèvre C; Lhermitte B; Ahle G; Chambrelant I; Cebula H; Antoni D; Keller A; Schott R; Thiery A; Constans JM; Noël G
    Crit Rev Oncol Hematol; 2021 Jan; 157():103188. PubMed ID: 33307200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
    Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
    Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
    Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
    Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
    Melguizo-Gavilanes I; Bruner JM; Guha-Thakurta N; Hess KR; Puduvalli VK
    J Neurooncol; 2015 May; 123(1):141-50. PubMed ID: 25894594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
    Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
    Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
    Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Yamaguchi S; Tanino M; Murata J; Houkin K
    Brain Tumor Pathol; 2013 Apr; 30(2):67-72. PubMed ID: 22752663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
    Strauss SB; Meng A; Ebani EJ; Chiang GC
    Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    Eur Radiol; 2018 Jun; 28(6):2628-2638. PubMed ID: 29374321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.
    Sidibe I; Tensaouti F; Roques M; Cohen-Jonathan-Moyal E; Laprie A
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.
    Ou SH; Klempner SJ; Azada MC; Rausei-Mills V; Duma C
    Lung Cancer; 2015 Jun; 88(3):355-9. PubMed ID: 25882777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
    Qian X; Tan H; Zhang J; Zhao W; Chan MD; Zhou X
    Med Phys; 2016 Nov; 43(11):5889. PubMed ID: 27806598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression.
    Hansen MR; Pan E; Wilson A; McCreary M; Wang Y; Stanley T; Pinho MC; Guo X; Okuda DT
    J Neurooncol; 2018 Sep; 139(3):731-738. PubMed ID: 29882044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
    Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC
    Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients.
    Yoo RE; Choi SH
    Magn Reson Med Sci; 2016; 15(2):165-77. PubMed ID: 26726012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preradiotherapy MR Imaging: A Prospective Pilot Study of the Usefulness of Performing an MR Examination Shortly before Radiation Therapy in Patients with Glioblastoma.
    Majós C; Cos M; Castañer S; Pons A; Gil M; Fernández-Coello A; Macià M; Bruna J; Aguilera C
    AJNR Am J Neuroradiol; 2016 Dec; 37(12):2224-2230. PubMed ID: 27609621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.